JP2022528851A5 - - Google Patents
Info
- Publication number
- JP2022528851A5 JP2022528851A5 JP2021557758A JP2021557758A JP2022528851A5 JP 2022528851 A5 JP2022528851 A5 JP 2022528851A5 JP 2021557758 A JP2021557758 A JP 2021557758A JP 2021557758 A JP2021557758 A JP 2021557758A JP 2022528851 A5 JP2022528851 A5 JP 2022528851A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- residue
- val
- cit
- compound according
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023002495A JP7680658B2 (ja) | 2019-03-29 | 2023-01-11 | 化合物及びその複合体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826393P | 2019-03-29 | 2019-03-29 | |
| US62/826,393 | 2019-03-29 | ||
| US202062964177P | 2020-01-22 | 2020-01-22 | |
| US62/964,177 | 2020-01-22 | ||
| PCT/EP2020/057984 WO2020200880A1 (en) | 2019-03-29 | 2020-03-23 | Compounds and conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023002495A Division JP7680658B2 (ja) | 2019-03-29 | 2023-01-11 | 化合物及びその複合体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022528851A JP2022528851A (ja) | 2022-06-16 |
| JP2022528851A5 true JP2022528851A5 (https=) | 2022-08-24 |
| JPWO2020200880A5 JPWO2020200880A5 (https=) | 2022-08-24 |
| JP7210770B2 JP7210770B2 (ja) | 2023-01-23 |
Family
ID=69960637
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557758A Active JP7210770B2 (ja) | 2019-03-29 | 2020-03-23 | 化合物及びその複合体 |
| JP2023002495A Active JP7680658B2 (ja) | 2019-03-29 | 2023-01-11 | 化合物及びその複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023002495A Active JP7680658B2 (ja) | 2019-03-29 | 2023-01-11 | 化合物及びその複合体 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20200306243A1 (https=) |
| EP (2) | EP4176904A1 (https=) |
| JP (2) | JP7210770B2 (https=) |
| KR (3) | KR102679892B1 (https=) |
| CN (4) | CN118240003A (https=) |
| AU (1) | AU2020252034B2 (https=) |
| BR (1) | BR112021018986A2 (https=) |
| CA (1) | CA3133757A1 (https=) |
| CL (1) | CL2021002498A1 (https=) |
| CO (1) | CO2021014566A2 (https=) |
| CR (1) | CR20210541A (https=) |
| DK (1) | DK3946464T3 (https=) |
| EC (1) | ECSP21078204A (https=) |
| ES (1) | ES2930295T3 (https=) |
| HR (1) | HRP20221280T1 (https=) |
| HU (1) | HUE060364T2 (https=) |
| IL (1) | IL286291B2 (https=) |
| LT (1) | LT3946464T (https=) |
| MX (1) | MX2021011812A (https=) |
| PH (1) | PH12021552363A1 (https=) |
| PL (1) | PL3946464T3 (https=) |
| PT (1) | PT3946464T (https=) |
| RS (1) | RS63715B1 (https=) |
| SG (1) | SG11202110524VA (https=) |
| SM (1) | SMT202200439T1 (https=) |
| TW (2) | TWI886667B (https=) |
| UA (1) | UA129129C2 (https=) |
| WO (1) | WO2020200880A1 (https=) |
| ZA (1) | ZA202106612B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| US11493668B2 (en) | 2018-09-26 | 2022-11-08 | Johnson & Johnson Vision Care, Inc. | Polymerizable absorbers of UV and high energy visible light |
| HUE060364T2 (hu) * | 2019-03-29 | 2023-02-28 | Medimmune Ltd | Vegyületek és konjugátumaik |
| TW202116356A (zh) | 2019-07-10 | 2021-05-01 | 美商斯布雷克薩三號公司 | 作為治療劑之微管靶向藥劑之肽結合物 |
| CN114341162B (zh) | 2019-07-10 | 2025-10-17 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
| TW202140076A (zh) * | 2020-01-22 | 2021-11-01 | 英商梅迪繆思有限公司 | 化合物及其軛合物 |
| WO2021148500A1 (en) * | 2020-01-22 | 2021-07-29 | Medimmune Limited | Compounds and conjugates thereof |
| KR20250120438A (ko) * | 2021-02-05 | 2025-08-08 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 캄프토테신 화합물, 그의 제조방법 및 그의 응용 |
| CN115703712A (zh) | 2021-08-17 | 2023-02-17 | 江苏迈威康新药研发有限公司 | 5,8-二氨基-3,4-二氢-2h-1-萘酮的合成方法以及其中采用的中间体化合物 |
| CN118414339A (zh) | 2021-12-16 | 2024-07-30 | 迈威(上海)生物科技股份有限公司 | 一种喜树碱类化合物及其偶联物 |
| TW202348252A (zh) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | 用治療性結合分子治療癌症的組合療法 |
| KR20240159839A (ko) | 2022-03-09 | 2024-11-06 | 아스트라제네카 아베 | FRα에 대한 결합 분자 |
| IL314452A (en) | 2022-03-11 | 2024-09-01 | Astrazeneca Ab | Scoring method for anti-frα antibody-drug treatment |
| KR20250024743A (ko) | 2022-03-23 | 2025-02-19 | 시나픽스 비.브이. | Trop-2를 발현하는 종양을 표적화하기 위한 항체-컨쥬게이트 |
| EP4496593A1 (en) | 2022-03-23 | 2025-01-29 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
| IL315366A (en) | 2022-03-23 | 2024-11-01 | Synaffix Bv | Antibody pairs for targeting PTK7-expressing tumors |
| IL315205A (en) | 2022-03-23 | 2024-10-01 | Synaffix Bv | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen |
| IL315393A (en) | 2022-03-25 | 2024-11-01 | Zymeworks Bc Inc | Antibody preparations for drugs targeting alpha acid receptor and methods of use |
| CN115160403B (zh) * | 2022-07-05 | 2025-06-27 | 博石丰生命科技(南通)有限公司 | 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法 |
| EP4583921A1 (en) * | 2022-09-07 | 2025-07-16 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Anti-trop2/egfr antibodies and uses thereof |
| TW202448517A (zh) | 2023-02-16 | 2024-12-16 | 瑞典商阿斯特捷利康公司 | 用治療性結合分子治療癌症的組合療法 |
| WO2024223899A1 (en) | 2023-04-28 | 2024-10-31 | Medimmune Limited | B7-h4 therapeutic binding molecules for the treatment of cancer |
| TW202508638A (zh) * | 2023-05-12 | 2025-03-01 | 大陸商百奧賽圖(北京)醫藥科技股份有限公司 | 連結子化合物及配體－藥物接合物、其製備方法及用途 |
| EP4721767A1 (en) | 2023-06-05 | 2026-04-08 | Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. | Anti-b7-h3 antibody or fragment thereof, and antibody drug conjugate targeting b7-h3 |
| WO2025027472A2 (en) | 2023-07-31 | 2025-02-06 | Astrazeneca Ab | Cd123 antibody-drug conjugates and methods of using the same |
| WO2025103192A1 (zh) * | 2023-11-16 | 2025-05-22 | 上海齐鲁制药研究中心有限公司 | 一种氘代喜树碱化合物及其制备和应用 |
| WO2025167743A1 (zh) * | 2024-02-06 | 2025-08-14 | 四川科伦博泰生物医药股份有限公司 | 抗体药物偶联物及其制备方法和用途 |
| WO2025167742A1 (zh) * | 2024-02-06 | 2025-08-14 | 四川科伦博泰生物医药股份有限公司 | 抗体药物偶联物及其制备方法和用途 |
| WO2025191470A1 (en) | 2024-03-12 | 2025-09-18 | Astrazeneca Ab | Processes and compounds for the preparation of topoisomerase i inhibitor linker-payloads |
| WO2026057740A1 (en) | 2024-09-12 | 2026-03-19 | Astrazeneca Ab | Treatment of cancer with therapeutic binding molecules |
| WO2026078620A1 (en) | 2024-10-11 | 2026-04-16 | Medimmune Llc | Cd22 antibody and drug conjugates and uses thereof |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4939255A (en) | 1987-06-24 | 1990-07-03 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic camptothecin derivatives |
| JP2754022B2 (ja) * | 1988-11-18 | 1998-05-20 | 第一製薬株式会社 | カンプトテシン類縁体 |
| JP3024013B2 (ja) * | 1990-08-14 | 2000-03-21 | 杏林製薬株式会社 | フルオロエチルカンプトテシン誘導体 |
| JP3008226B2 (ja) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| US6407115B1 (en) | 1991-01-16 | 2002-06-18 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic compound |
| US5658920A (en) | 1991-01-16 | 1997-08-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound |
| JP3359955B2 (ja) * | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| US5849945A (en) | 1995-02-22 | 1998-12-15 | Daiichi Pharmaceutical Co., Ltd. | Aminotetralone derivatives and preparation process thereof |
| US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
| US5663177A (en) | 1995-05-31 | 1997-09-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs |
| JPH1095802A (ja) * | 1995-12-28 | 1998-04-14 | Tanabe Seiyaku Co Ltd | カンプトテシン誘導体 |
| IN189180B (https=) | 1997-07-09 | 2003-01-04 | Chong Kun Dang Corp | |
| AR030207A1 (es) | 2000-04-07 | 2003-08-13 | Daiichi Seiyaku Co | Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma |
| US6403604B1 (en) * | 2001-03-01 | 2002-06-11 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
| WO2002090315A1 (en) | 2001-05-08 | 2002-11-14 | Mitsui Chemicals, Inc. | Process for preparation of 1,5-diaminonaphthalenes |
| DE60227113D1 (de) | 2001-11-30 | 2008-07-24 | Chugai Pharmaceutical Co Ltd | Kondensierte camptothecine als antitumormittel |
| EP1599484A2 (en) | 2003-02-21 | 2005-11-30 | Chugai Seiyaku Kabushiki Kaisha | Process for the preparation of hexacyclic camptothecin derivatives |
| RU2413731C2 (ru) | 2004-04-09 | 2011-03-10 | Чугаи Сейяку Кабусики Кайся | Новые растворимые в воде пролекарства |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| HRP20110498T1 (hr) | 2005-10-07 | 2011-08-31 | Exelixis | Azetidini kao inhibitori mek za liječenje proliferativnih bolesti |
| SI1813614T1 (sl) | 2006-01-25 | 2012-01-31 | Sanofi 174 | Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate |
| EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| MX2010003718A (es) | 2007-10-19 | 2010-04-21 | Genentech Inc | Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo. |
| KR20200058590A (ko) | 2008-04-30 | 2020-05-27 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| US8980909B2 (en) * | 2011-01-12 | 2015-03-17 | Crystal Biopharmaceutical Llc | HDAC inhibiting derivatives of camptothecin |
| CN102850400A (zh) * | 2011-06-30 | 2013-01-02 | 周文强 | 喜树碱衍生物及其制备方法、药物组合物与用途 |
| DK2907824T3 (en) * | 2012-10-11 | 2018-07-23 | Daiichi Sankyo Co Ltd | ANTIBODY-drug conjugate |
| EP2910573B1 (en) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| US9962452B2 (en) * | 2013-02-04 | 2018-05-08 | Zhuhai Beihai Biotech Co., Ltd. | Soluble complexes of drug analogs and albumin |
| WO2015081282A1 (en) * | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| LT3424955T (lt) | 2013-12-25 | 2025-06-25 | Daiichi Sankyo Company, Limited | Anti-trop2 antikūno ir vaisto konjugato gamybos būdas |
| SI3466976T1 (sl) | 2014-01-31 | 2021-12-31 | Daiichi Sankyo Company, Limited | Anti-her2 konjugat protitelesa-zdravila |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| KR102399277B1 (ko) | 2014-04-10 | 2022-05-18 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| JP6612738B2 (ja) | 2014-04-10 | 2019-11-27 | 第一三共株式会社 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| WO2016053107A1 (en) | 2014-10-03 | 2016-04-07 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
| HUE055644T2 (hu) | 2015-01-30 | 2022-03-28 | Sutro Biopharma Inc | Hemiasterlin származékok konjugációra és terápiára |
| GB201506393D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| EP4180455A1 (en) | 2015-06-29 | 2023-05-17 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| EP3362100B1 (en) * | 2015-10-16 | 2022-06-22 | Genentech, Inc. | Hindered disulfide drug conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| SG10201912173RA (en) | 2016-10-07 | 2020-02-27 | Daiichi Sankyo Co Ltd | Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate |
| WO2018089393A1 (en) | 2016-11-10 | 2018-05-17 | Medimmune, Llc | Binding molecules specific for asct2 and uses thereof |
| BR112019011794A2 (pt) | 2016-12-12 | 2019-10-29 | Daiichi Sankyo Co Ltd | composição farmacêutica, e, método terapêutico. |
| CA3050668C (en) | 2017-01-17 | 2023-08-15 | Daiichi Sankyo Company, Limited | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
| KR20240074000A (ko) | 2017-02-28 | 2024-05-27 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법 |
| TW202532102A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| CN109106951A (zh) | 2017-08-18 | 2019-01-01 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| CN108853514B (zh) | 2017-08-18 | 2022-07-22 | 四川百利药业有限责任公司 | 具有两种不同药物的抗体药物偶联物 |
| HUE060364T2 (hu) * | 2019-03-29 | 2023-02-28 | Medimmune Ltd | Vegyületek és konjugátumaik |
-
2020
- 2020-03-23 HU HUE20713873A patent/HUE060364T2/hu unknown
- 2020-03-23 CN CN202410334103.5A patent/CN118240003A/zh active Pending
- 2020-03-23 AU AU2020252034A patent/AU2020252034B2/en active Active
- 2020-03-23 BR BR112021018986A patent/BR112021018986A2/pt unknown
- 2020-03-23 LT LTEPPCT/EP2020/057984T patent/LT3946464T/lt unknown
- 2020-03-23 JP JP2021557758A patent/JP7210770B2/ja active Active
- 2020-03-23 KR KR1020237003605A patent/KR102679892B1/ko active Active
- 2020-03-23 IL IL286291A patent/IL286291B2/en unknown
- 2020-03-23 SM SM20220439T patent/SMT202200439T1/it unknown
- 2020-03-23 SG SG11202110524VA patent/SG11202110524VA/en unknown
- 2020-03-23 HR HRP20221280TT patent/HRP20221280T1/hr unknown
- 2020-03-23 PT PT207138736T patent/PT3946464T/pt unknown
- 2020-03-23 US US16/826,405 patent/US20200306243A1/en not_active Abandoned
- 2020-03-23 CA CA3133757A patent/CA3133757A1/en active Pending
- 2020-03-23 KR KR1020217035043A patent/KR102498681B1/ko active Active
- 2020-03-23 DK DK20713873.6T patent/DK3946464T3/da active
- 2020-03-23 EP EP22189090.8A patent/EP4176904A1/en active Pending
- 2020-03-23 CN CN202410334111.XA patent/CN118221763A/zh active Pending
- 2020-03-23 WO PCT/EP2020/057984 patent/WO2020200880A1/en not_active Ceased
- 2020-03-23 CN CN202080025199.7A patent/CN113631196B/zh active Active
- 2020-03-23 MX MX2021011812A patent/MX2021011812A/es unknown
- 2020-03-23 KR KR1020247021308A patent/KR20240104214A/ko active Pending
- 2020-03-23 PH PH1/2021/552363A patent/PH12021552363A1/en unknown
- 2020-03-23 CR CR20210541A patent/CR20210541A/es unknown
- 2020-03-23 ES ES20713873T patent/ES2930295T3/es active Active
- 2020-03-23 CN CN202311084298.4A patent/CN117263948B/zh active Active
- 2020-03-23 US US17/599,374 patent/US20220211863A1/en active Pending
- 2020-03-23 RS RS20221023A patent/RS63715B1/sr unknown
- 2020-03-23 PL PL20713873.6T patent/PL3946464T3/pl unknown
- 2020-03-23 UA UAA202105856A patent/UA129129C2/uk unknown
- 2020-03-23 EP EP20713873.6A patent/EP3946464B1/en active Active
- 2020-03-27 TW TW112146860A patent/TWI886667B/zh active
- 2020-03-27 TW TW109110410A patent/TWI826676B/zh active
-
2021
- 2021-06-15 US US17/348,236 patent/US11446292B2/en active Active
- 2021-09-08 ZA ZA2021/06612A patent/ZA202106612B/en unknown
- 2021-09-27 CL CL2021002498A patent/CL2021002498A1/es unknown
- 2021-10-22 EC ECSENADI202178204A patent/ECSP21078204A/es unknown
- 2021-10-28 CO CONC2021/0014566A patent/CO2021014566A2/es unknown
-
2023
- 2023-01-11 JP JP2023002495A patent/JP7680658B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022528851A5 (https=) | ||
| JPWO2020200880A5 (https=) | ||
| JP7447183B2 (ja) | 親水性抗体－薬物コンジュゲート | |
| HRP20221280T1 (hr) | Spojevi i njihovi konjugati | |
| JP6117921B2 (ja) | 細胞毒性剤と細胞結合受容体との共役体 | |
| CA2944699C (en) | Affinity medicant conjugates | |
| JP2017537893A5 (https=) | ||
| CA3207893A1 (en) | Immunomodulatory antibody-drug conjugates | |
| CN110392685B (zh) | 苯并二氮卓衍生物的选择性磺化 | |
| CA2988806A1 (en) | Conjugates of cysteine engineered antibodies | |
| JP2021536430A (ja) | リンカー、それを含む抗体薬物コンジュゲート、およびその使用 | |
| CN112601522A (zh) | 抗体-alk5抑制剂偶联物及其用途 | |
| JP6585650B2 (ja) | 細胞毒性剤と細胞結合受容体との共役体 | |
| CN114269388A (zh) | 抗体-alk5抑制剂缀合物及其用途 | |
| US12280021B2 (en) | Affinity medicant conjugate | |
| WO2022001710A1 (zh) | 用于抗体与药物偶联体(adc)制备的中间体及其制备方法和应用 | |
| JPWO2021148500A5 (https=) | ||
| JP5341314B2 (ja) | 薬物送出系 | |
| HK40065597A (en) | Hydrophilic drug-linker compounds | |
| JP2019167359A (ja) | 細胞毒性剤と細胞結合受容体との共役体 | |
| NZ722252B2 (en) | Hydrophilic antibody-drug conjugates | |
| NZ761642B2 (en) | Hydrophilic antibody-drug conjugates | |
| NZ761644B2 (en) | Hydrophilic antibody-drug conjugates | |
| NZ761646B2 (en) | Hydrophilic antibody-drug conjugates |